UCB : Financial Reporting Document

Key modelling data for UCB half-year results 2024 and remindersAs of June 25, 2024 for second half 2024

The UCB IR Team has compiled the following items to assist capital market participants in preparation of the upcoming half-year results 2024 publication, scheduled for July 25, 2024.

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

LatestFull-Yeardata here2023 results

Revenue:Guidance€5.5 -20245.7bn

Adjusted EBITDA: 23 - 24.5%

Core EPS: €3.70 - 4.40

R&D expenses flat in absolute terms

Tax rate expected around 15%

: There was a sale of an established brands portfolio of 5 prescription medicines, in a variety of non-core therapeuticReminder categories commercialized in Europe, for €145mn in Q1/2023. No such sale in H1 2024 (different phasing for this ongoing activity in 2024).

GrowthMain driversriversBIMZELXfor guidance, BRIVIACT 2024, FINTEPLA , RYSTIGGO , ZILBRYSQ , EVENITY

Solid performance CIMZIA®®®®®®®

Accelerated investment behind the launches including U.S. Direct to Consumer (DTC) campaign for BIMZELX® (started in March)

Stable R&D expenses in absolute terms

Strong contribution (via other operating income line of the P&L) from EVENITY®

Continue to manage the tail end of the portfolio

1

Revenue: at least €6bn		at the lower end of the range
Guidance 2025		)
Adjusted EBITDA: low- to mid-thirties % (
Improved ESG rating performance	on our website.Consensus H1 2024 estimates have been included.
Latest VisibleAlpha consensus available®
Consensus

bimekizumab/BIMZELX
Global peak sales guidance of >€4bn announced in October 2023
Reaching over 20,000 patients (as per last communication Q1/2024)
US:	Approved for Psoriasis (PSO) in October 2023, launched inNovember 2023; filed for Psoriatic Arthritis (PsA),
	Ankylosing Spondylitis (AS), non-radiographicAxial Spondylarthritis (nr-axSpA) in Q1 2024 and Hidradenitis
	Formulary access		in Q2 2024. FDA action expected by end 2024.
	Suppurativa (HS) and 2mL device®
		: BIMZELX covered andavailable for 6 out of 10 commercially insured lives (Double-step edit or
	Paid to bridge ratio
	better) - as per February 2024
EU:	February 2024	: at30%/70% as per February 2024 with intent to increase to 50%/50% by Q4 2024 - as per
Launched for PSO; PsA and axial Spondyloarthritis (AS & nr-axSpA) in 2023.
	Approved in HS in April 2024. Launched in April in Germany and Austria. EU Early Access Program underway in
	severalcountries
Japan:	Positive CHMP opinionfor 2mL device in May 2024.
Launched for PSO; Approved for PsA, AS and nr-axSpA in December 2023; Filed for HS in Q4/2023

	®
First presentation of four-year BIMZELX (bimekizumab-bkzx) data in March 2024
Publication in the Lancet of phase 3®bimekizumab trial results in moderate tosevere HS in May 2024
brivaracetam/BRIVIACT
US:	Loss of exclusivity February 20261 1
EU:	Loss of exclusivity August 2026
Japan:	Approved in June 2024
Peak sales guidance of at least€600m by 2026

CIMZIA®
Peak sales guidance: >€2.0bn by 2024 - achieved in 2022
US:	Loss of exclusivity February 2024
EU:	Loss of exclusivity October 20241
Japan:	Loss of exclusivity June 2026

Current assumption for first possible biosimilar market entry: 2028 (no listing on clinicaltrials.gov as of now) Presentation at EULAR of data supporting the value of CIMZIA® in RA throughout pregnancy and post-partum, and for high rheumatoid factor levels June 2024

EvenityEVENITYis being® developed and commercialized in collaboration with Amgen globally, as well as with Astellas in Japan UCB books the EU sales and EU OPEX, Amgen books US, Japan and RoW sales, details on slide 27 in our Facts & Figures50/50 net profit split booked in "Other operating income".

Amgen reported Q1/2024 net sales of US$ 342mn (Slide 8 in Amgen's Q1 presentation), +35% YoY growth.

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY® can help to close the treatment gap in osteoporosis in April 2024

2

Japan:FINTEPLA®approved for Lennox-Gastaut syndrome (LGS) in April 2024

Loss of Exclusivity: Q4 20331

Data presented on final open-label extension FINTEPLA® at International Child Neurology Congress (ICNC) Annual Meeting in May 2024

SalesNEUPRO®now included in "Established Brands", after loss of exclusivity in 2021

US:	Loss of exclusivity March 2022
VIMPAT®
EU:	Erosion has bottomed out through 2023.
Loss of exclusivity September 2022
	Erosion has bottomed out through 2023.
Japan: Loss of exclusivity July 2024. Generic entry expected as of 2025.
US:	Approved for generalized Myasthenia Gravis (gMG) in June 2023following priority review by FDA, launched in July
rozanolixizumab/RYSTIGGO®
2023	Approved for generalized Myasthenia Gravis (gMG) in January 2024, launches started in Q1/2024.
EU:
Japan:	Approved for gMG in September 2023,launched in Q4 2023.
US:	Approved for gMG in September 2023
zilucoplan/ZILBRYSQ®
EU:	Approved for gMG in December 2023
Japan:	Approved for gMG in September 2023

Global launches started in Q1/2024

Data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ® (zilucoplan) in May 2024

OECDTax minimumrate 2024tax rate of 15% has come into effect in 2024. UCB's tax rate for 2024 is expected to be around 15%.

InDebtMarchfinancing, UCB successfully completed the placement of EUR 500 million senior unsecured bonds with a coupon of 4.25% and atenor of 6 years. The bonds are issued under UCB's EUR 5 billion EMTN Programme on 20 March 2024. PipelinePipelineon our website

Update due July 25,2024

1. Earliest expected Loss of Exclusivity dates are indicative

3